Severe allergic rhinitis (e.g., chronic allergic rhinitis or rhinitis with nasal polyps) is a complex condition that may not respond adequately to traditional treatments such as topical steroids or antihistamines. In such cases, **biological drugs** emerge as an advanced and effective option targeting specific immune mechanisms driving inflammation. <br />Main Biologic Drugs Used <br />1. Omalizumab <br /> - Mechanism: A monoclonal antibody that binds to IgE (immunoglobulin E), preventing its interaction with mast cells and basophils, thereby reducing allergic responses. <br /> - Use: Approved for severe allergic asthma and rhinitis, particularly in patients unresponsive to conventional therapies¹. <br />2. Dupilumab <br /> - Mechanism: Inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, key molecules in the Th2 immune pathway linked to allergic inflammation. <br /> - Use: Effective for chronic rhinosinusitis with nasal polyps (CRSwNP), reducing polyp size and improving nasal airflow². <br />3. Mepolizumab and Reslizumab <br /> - Mechanism: Target interleukin-5 (IL-5), which stimulates eosinophil growth and activation—central players in allergic inflammation. <br /> - Use: Used in severe cases with elevated eosinophil levels³. <br />4. Benralizumab <br /> - Mechanism: Binds to the IL-5 receptor (IL-5R), inducing eosinophil destruction via antibody-dependent cellular cytotoxicity. <br />Efficacy of Biologic Therapy <br />A-Symptom Improvement: Studies show significant reductions in sneezing, nasal congestion, eye itching, and improved sleep quality⁴. <br />B-Reduced Steroid Dependence: Lowers the need for systemic steroids, avoiding their long-term side effects. <br />C-Long-Term Outcomes: Sustained symptom relief for up to 52 weeks after treatment initiation⁵. <br />Challenges and Considerations <br />1-High Cost : Biologic drugs are significantly more expensive than traditional therapies, limiting accessibility. <br />2-Administration : Typically given as subcutaneous or intravenous injections, requiring regular medical visits. <br />Side Effects: <br /> - Local injection-site reactions. <br /> - Rare systemic effects (e.g., headaches, hypersensitivity). <br />Future Directions: <br />1-Novel Therapies: Drugs like **Tezepelumab**, which targets TSLP (thymic stromal lymphopoietin), a key initiator of allergic responses, are under investigation⁶. <br />2-Personalized Medicine: Biomarkers (e.g., IgE levels, eosinophil counts) are being used to tailor treatments to individual patients. <br />Conclusion <br />Biologic therapies represent a breakthrough in managing severe allergic rhinitis, particularly for treatment-resistant cases. These drugs exemplify the shift toward precision medicine—targeting disease mechanisms rather than merely alleviating symptoms. <br /><br /> Dr.Ali Hussein Hamzah Alnasrawi<br />